The terminal complement C5 inhibitor ravulizumab was engineered from the humanized
monoclonal antibody eculizumab to have an extended half-life and duration of action. It …

Introduction Myasthenia gravis (MG) is a neurological B-cell mediated autoimmune disorder
affecting the neuromuscular junction. MG therapeutics have always relied on nonselective …

Ravulizumab (ULTOMIRIS®) is the first long-acting complement C5 inhibitor (administered
intravenously every 8 weeks) to be approved in several countries globally, for adults with …

Introduction The terminal complement C5 inhibitor ravulizumab has a long elimination half-
life, allowing maintenance dosing every 8 weeks. In the 26-week, double-blind, randomized …

Abstract Introduction/Aims The CHAMPION MG study demonstrated that ravulizumab
significantly improved Myasthenia Gravis‐Activities of Daily Living (MG‐ADL) and …

Introduction Ravulizumab demonstrated efficacy and an acceptable safety profile versus
placebo in the randomized controlled period (RCP) of the phase 3 CHAMPION MG trial in …

Objective: To evaluate the efficacy and safety of ravulizumab in adults with anti-acetylcholine
receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG). Background …

Background Generalized myasthenia gravis (gMG) is a rare, chronic, and debilitating
autoimmune disease. Activation of the complement system by autoantibodies against the …

Objective: To investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of the
long-acting terminal complement C5 inhibitor ravulizumab in adults with anti-acetylcholine …

Objective: To evaluate the long-term efficacy and safety of ravulizumab in adults with anti-
acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG) …